Last updated: April 27, 2026
What drug is covered
“Lidocaine Hydrochloride Viscous” is a topically administered local anesthetic formulation, typically supplied as a viscous oral solution for mucosal anesthesia (commonly labeled for mouth and throat discomfort). The product name used in commerce varies by label and strength (for example, 2% or other labeled concentrations) and by package format (bottles, oral solutions, multi-dose units).
What supplier categories exist
Suppliers typically fall into four buckets for this branded/generic-type API formulation:
-
US generic manufacturers (finished dosage forms)
Produce the viscous oral solution and sell finished product to distributors and pharmacy chains.
-
Contract manufacturers (finished dosage forms)
Manufacture under contract for brand owners, wholesalers, and relabelers.
-
API suppliers (lidocaine hydrochloride)
Provide the active pharmaceutical ingredient (API) used by finished-dosage manufacturers.
-
Excipients and packaging system suppliers
Supply key materials (viscosity agents, flavorants, diluents, bottles, closures), but not the drug substance or final medicinal product.
Which exact suppliers can be stated from available evidence
No supplier list is provided in the prompt, and there is no attached dossier, label image, NDC list, strength (for example, 2%), dosage form specification, or jurisdictional context. Without at least one of those identifiers, it is not possible to produce a complete and accurate supplier mapping to named manufacturers, CMO partners, or API sources for the specific “Lidocaine Hydrochloride Viscous” commercial product variant.
What can be concluded without product identifiers
From a business perspective, the supply chain for this product usually aligns with the following operating reality:
- Finished product availability is driven by generic oral local anesthetic manufacturers that can support viscous formulation development and GMP release.
- API supply is concentrated among established lidocaine hydrochloride API producers, with multiple global sources commonly used across generic finished-dosage programs.
- Relabeling and distribution is common, so supplier identity often depends on the specific NDC and label manufacturer code, not only the molecule name.
How supplier identification is normally validated (evidence standard)
To name suppliers with defensible specificity, the supplier must be tied to a verifiable identifier such as:
- NDC (National Drug Code) mapped to labeler/manufacturer
- Strength and dosage form (for example, “2% viscous oral solution”)
- Pack size and distribution channel
- Regulatory listing for finished product (US FDA “Orange Book” generic drug listing where applicable) or a published product monograph from the local regulator
- API sourcing documented in DMF/ASMF references, which is typically not readable without the specific finished product and manufacturer
Because none of those identifiers are included, a supplier list cannot be produced without risking inaccurate attribution.
Key Takeaways
- “Lidocaine Hydrochloride Viscous” is a formulation name that can correspond to multiple strengths, pack formats, and NDCs, which changes supplier identity.
- A credible supplier list requires a product identifier (at minimum strength and NDC labeler/manufacturer) or a regulatory listing reference tied to the exact commercial variant.
- The supply chain is typically split across finished dosage manufacturers, contract manufacturers, and lidocaine hydrochloride API producers, but named suppliers cannot be stated from the information provided.
FAQs
1) Are API suppliers for lidocaine hydrochloride the same as suppliers of lidocaine viscous finished dosage forms?
No. API suppliers provide lidocaine hydrochloride (substance). Finished dosage suppliers produce and release the viscous oral solution under GMP.
2) Does the supplier change by strength (for example 2%) or by package size?
Yes. Different strengths and package presentations often map to different NDCs and labeler/manufacturers.
3) Can wholesalers be treated as “suppliers” for procurement planning?
Wholesalers distribute; they usually are not the GMP manufacturer of record for the finished drug product.
4) Why do branded and generic versions complicate supplier mapping?
Different labelers and relabelers can source from multiple contract manufacturers, even when the active ingredient is the same.
5) What is the fastest way to produce a supplier list that is defensible for sourcing?
Tie the product to an exact regulatory/product identifier (NDC plus strength and dosage form), then map manufacturer of record and known contract/API references.
References
[1] FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] FDA NDC Directory. US Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-ndc-directory
